Literature with regard to coronavirus disease 2019 (COVID-19) associated morbidities and the risk factors for death are still emerging. In this study, we investigated the presence of kidney damage ...

(1) Background: Standard semen analysis methods may exhibit variability between observers and/or human error; therefore, additional methods are needed to overcome these handicaps. We aimed to present a new smartphone-applied semen analyzer, Sperm Cell™, investigate its diagnostic efficacy by comparing it with the standard analysis method, and determine its user-friendly nature. (2) Methods: A cross-sectional study was conducted on a large sample cohort, including 102 men. Three semen analyses were performed for each semen sample. The first employed the standard manual method, whereas the others were smartphone-based analyses performed by technicians and patients. We compared major semen parameters between the three semen analyses. The user-friendly nature of the analyzer was also evaluated with a mini-questionnaire completed by the participants. (3) Results: The determined median sperm count, motile sperm count, and percentage of motile sperms, on standard manual semen analysis, were 50.00 × 10⁶/mL (0–160 × 10⁶/mL), 23.94 × 10⁶/mL (0–108 × 10⁶/mL) and 50.00% (0–73.00%), respectively. Median sperm count and motile sperm count were 50.52 × 10⁶/mL (<1–150 × 10⁶/mL) vs. 55.77 × 10⁶/mL ( 0.05 for each). The SpermCell™ analysis results were correlated with the standard manual method with up to 0.85 correlation coefficients. Moreover, substantial diagnostic accuracy, sensitivity and specificity were obtained in determining the oligospermia and asthenozoospermia via the device-based analyses performed by technician and patients. The mini-questionnaire results revealed that the analyzer is useful. (4) Conclusions: The novel smartphone-applied semen analyzer is a helpful tool with acceptable diagnostic accuracy in determining the major semen parameters. It can be used as an efficient at-home point-of-care testing method in the initial assessment of couples with infertility concerns.

E21050 Background: Colorectal cancer has an important place in worldwide death from cancer causes. Angiogenesis, in which angiogenic factors such as VEGF and basic FGF have a key role, is an important factor in patient survival with respect to progression and metastatic spreading in colorectal cancer. In this study, we aimed to determine that whether serum VEGF and bFGF pre- and post-treatment serum levels are decisive in evaluating response to treatment and progression in metastatic colorectal cancer (mCRC) patients treated with FOLFIRI-bevacizumab. Methods: In 33 mCRC patients treated in our department serum VEGF and bFGF levels were monitored in the beginning of treatment and until progression during FOLFIRI-bevacizumab treatment before 4.-, 8.- and 12.-regimens. Serum levels of VEGF and bFGF were assssed using the quantitative sandwich enzyme immunoassay technique. Results: In our study serumVEGF and bFGF levels were significantly higher than the healthy controls (p<0.001). We found that the patients with pre-treatment high serum bFGF levels have significantly short PFS and with pre-treatment high serum LDH levels have significantly short overall survival (OS). In patients with pre-treatment low serum VEGF value (< 147.79 pg/ml) had significantly longer OS (27.93 vs 23.27 mounts, P:0.026) in metastatic rectum cancer. In multivariate analysis were found to be prognostic factors VEGF levels and side of tumor for PFS and VEGF levels and whether to be operated of tumor for OS. Conclusions: Serum VEGF level was detected to be one of the factors that determine PFS and OS in mCRC. Pretreatment serum bFGF levels were determined PFS and monitorization of serum bFGF during treatment was found to be releated to response to treatment. Pretreatment serum LDH level was detected to determine OS in metastatic CRC. Although there was no statistical significance, in mCRC patients, whose pretreatment serum VEGF were high, PSK was longer with bevacizumab treatment. The important of pretreatment high serum VEGF level to select for treatment of bevacizumab will be planed in metastatic CRC requires to be confirmed in comprehensive, prospective studies.

Objective. To present complications of pubovaginal sling surgery (PVS) and their managements.Methods. A total of 21 patients who underwent PVS in 4 different tertiary refferal centers between June 2014 and May 2016 were reviewed retrospectively. Demographic characteristics of the patients, previous 6 history, daily pad use, Urogenital Distress Inventory (UDI-6) and Incontinence Impact Questionnaire (IIQ) were recorded. Also, the management of the complications were stated.Results. The mean age of the patients were 54.9±12.32 (range, 36-76) years. Six (28.5%) patients had a history of previous incontinence surgery and 15 (71.4%) patients were naïve. There were no intraoperative complications. The mean daily pad use was decreased from 4.04±0.95 to 0.95±0.86 (p=0.0001). While mean preoperative UDI-6 scores were decreased from 6.66±2.09 to 2.09±1.22 (p=0.0001) at postoperative sixth month; preoperative mean IIQ-7 scores decreased from 16.8±1.16 to 5.09±4.21 (p=0.0001) at postoperative sixth month. One (4.76%) patient had abdominal hernia at postoperative 2nd year, three (14.28%) patients had an increased post-micturational residual (150-200ml) and two (9.52%) patients had urinary retention. Conclusion. Although the efficiency of PVS is high; one should aware of complications. The successful management of the complications will increase efficiency and patient satisfaction.

Study demonstrated that antibiotic resistance in the treatment of uncomplicated urinary tract infections varies by geographical region. We believe this comprehensive, national prospective study will provide valuable insights for clinicians planning empirical treatment for uncomplicated urinary tract infections.